Search Within

Andrew D Zelenetz

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (61)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (127)
  2. Center for Hematologic Malignancies (127)
  3. Department of Medicine (127)
  4. Epidemiology and Biostatistics (127)
  5. Hematologic Malignancies, Division of (127)
  6. Lymphoma (127)

More Groups

People
  1. Craig Moskowitz (66)
  2. Paul Hamlin (56)
  3. Anas Younes (51)
  4. Ariela Noy (49)
  5. David Straus (48)
  6. Anita Kumar (47)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (9)
  4. 2022 (5)
  5. 2021 (11)
  6. 2020 (8)

More Years

Publications
  1. Blood (52)
  2. Journal of Clinical Oncology (13)
  3. Hematological Oncology (10)
  4. British Journal of Haematology (8)
  5. Blood Advances (5)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (57)
  2. American Society of Clinical Oncology (13)
  3. Wiley Blackwell (10)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons (8)
  6. Elsevier Inc. (7)

More Publishers

Results (127)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schòˆder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma
    Journal Article

    Fischer, T.; Ni, A.; Bantilan, K. S.; Soumerai, J. D.; Alperovich, A.; Batlevi, C.; Younes, A.; Zelenetz, A. D.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J. R.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Copley, D.; Grieve, C.; Jacob, A. P.; Joseph, A.; Laraque, L.; more...
    Blood (2021)

    Fulltext@MSK | Save